Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12492248rdf:typepubmed:Citationlld:pubmed
pubmed-article:12492248lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0029408lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0027396lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0762662lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C0439230lld:lifeskim
pubmed-article:12492248lifeskim:mentionsumls-concept:C2926735lld:lifeskim
pubmed-article:12492248pubmed:issue6lld:pubmed
pubmed-article:12492248pubmed:dateCreated2002-12-20lld:pubmed
pubmed-article:12492248pubmed:abstractTextTo compare the efficacy and safety of rofecoxib 12.5 mg once daily to naproxen 500 mg twice daily in patients > or = 40 years of age with knee or hip osteoarthritis (OA).lld:pubmed
pubmed-article:12492248pubmed:languageenglld:pubmed
pubmed-article:12492248pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:citationSubsetIMlld:pubmed
pubmed-article:12492248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12492248pubmed:statusMEDLINElld:pubmed
pubmed-article:12492248pubmed:issn0300-9742lld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:ChowC TCTlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:ChenS LSLlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:PaseroGGlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:ILGVVlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:MoanAAlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:LaurenziMMlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:SarembockBBlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:Myllykangas-L...lld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:VrijensFFlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:RodgersD BDBlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:ChoonDDlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:AmanteCClld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:GentiGyGlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:ZerbiniC A...lld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:De ToraLLlld:pubmed
pubmed-article:12492248pubmed:authorpubmed-author:Naproxen...lld:pubmed
pubmed-article:12492248pubmed:issnTypePrintlld:pubmed
pubmed-article:12492248pubmed:volume31lld:pubmed
pubmed-article:12492248pubmed:ownerNLMlld:pubmed
pubmed-article:12492248pubmed:authorsCompleteYlld:pubmed
pubmed-article:12492248pubmed:pagination337-44lld:pubmed
pubmed-article:12492248pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:meshHeadingpubmed-meshheading:12492248...lld:pubmed
pubmed-article:12492248pubmed:year2002lld:pubmed
pubmed-article:12492248pubmed:articleTitleComparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.lld:pubmed
pubmed-article:12492248pubmed:affiliationKuopio University Hospital, Kuopio, Finland.lld:pubmed
pubmed-article:12492248pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12492248pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12492248pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12492248pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12492248pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12492248pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12492248lld:pubmed